undamentalytics Newsletter

Orbimed Advisors LLC: insider trades

Director, 10% owner at 20 companies we cover. 22 open-market purchases and 34 sales not made under a pre-set plan, reported from March 23, 2011 to June 24, 2026.

Would copying Orbimed Advisors LLC’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 13 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on May 23, 2016 into $9,603 by November 2, 2026, −0.4% a year. The copy held shares only 46% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $23,020, +8.3% a year (the S&P 500 held throughout made $43,610, +15.2% a year). Beta against the index was 0.47. Twelve months after each report, the average purchase was −31.8% against the S&P 500 (median −48.7%), and 8% beat it. Measured from the trade date, the insider’s own timing, the average was −23.5%. After their sales, the shares moved −12.0% against the index over 12 months on average (a negative figure means selling was the right call); 65% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201620182020202220242026 $43.6k$23.0k$9.6k
Copying Orbimed Advisors LLCS&P 500, same days investedS&P 500, held throughout $10,000 copying Orbimed Advisors LLC’s open-market purchases from May 23, 2016, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−0.4%
S&P 500, same days invested
+8.3% (held throughout +15.2%)
Time in shares
46%
Sharpe ratio (S&P 500)
0.19 (0.75)
Biggest drop (S&P 500)
−86% (−34%)
Market sensitivity (beta)
0.47
Purchases copied
13

Trade by trade

Orbimed Advisors LLC: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 13 +5.7% +10.2% 62% 5 −0.11 0.92 No reliable evidence
Purchases, 6 months after the report 13 −4.0% −8.4% 15% 5 0.28 0.79 No reliable evidence
Purchases, 12 months after the report 13 −31.8% −48.7% 8% 5 −0.15 0.89 No reliable evidence
Purchases, 12 months after the trade 11 −23.5% −41.0% 18% 4 0.35 0.75 No reliable evidence
Sales, 3 months after the report 25 +5.5% −4.0% 60% 10 0.44 0.67 No reliable evidence
Sales, 12 months after the report 23 −12.0% −24.7% 65% 9 −1.22 0.26 No reliable evidence
Sales, 12 months after the trade 23 −14.5% −31.5% 65% 9 −1.29 0.23 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Corvus Pharmaceuticals, Inc. CRVS —71May 20, 2016July 1, 2025
Alector, Inc. ALEC —07December 19, 2019April 16, 2020
Passage BIO, Inc. PASG —15June 29, 2023June 26, 2025
Kala BIO, Inc. KALA —40January 12, 2018February 12, 2018
Inspire Medical Systems, Inc. INSP —04March 11, 2019August 14, 2020
Neuropace Inc NPCE —04April 23, 2024May 16, 2025
Amarin Corp plc\uk AMRN —03March 23, 2011June 19, 2012
Compass Therapeutics, Inc. CMPX —30June 23, 2020November 10, 2022
Glaukos Corp GKOS —02August 12, 2016March 6, 2018
Disc Medicine, Inc. IRON —11February 17, 2023March 26, 2025
Tela Bio, Inc. TELA —02April 21, 2023July 2, 2024
Adicet Bio, Inc. ACET —20June 29, 2023October 10, 2025
Enliven Therapeutics, Inc. ELVN —02June 17, 2026June 24, 2026
Spyre Therapeutics, Inc. SYRE —10February 21, 2017February 21, 2017
Xtant Medical Holdings, Inc. XTNT —10February 23, 2018February 23, 2018
Palvella Therapeutics, Inc. PVLA —01May 2, 2018May 2, 2018
Whitehawk Therapeutics, Inc. WHWK —10July 2, 2018July 2, 2018
Calcimedica, Inc. CALC —10September 29, 2020September 29, 2020
Damora Therapeutics, Inc. DMRA —01April 17, 2023April 17, 2023
PMV Pharmaceuticals, Inc. PMVP —01September 12, 2025September 12, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
June 24, 2026June 22, 2026 ELVN Sale $39,014,046 −12.8%not yetnot yet
June 17, 2026June 15, 2026 ELVN Sale $12,668,988 +7.4%not yetnot yet
October 10, 2025October 8, 2025 ACET Purchase $5,000,000 not yetnot yetnot yet
September 12, 2025September 10, 2025 PMVP Sale $900,000 not yetnot yetnot yet
July 1, 2025June 27, 2025 CRVS Sale $4,893,541 not yetnot yetnot yet
June 26, 2025June 24, 2025 PASG Sale $197,239 not yetnot yetnot yet
May 16, 2025May 14, 2025 NPCE Sale $2,665,333 −59.3%−30.3%−28.8%
April 24, 2025April 22, 2025 PASG Sale $78,731 not yetnot yetnot yet
March 26, 2025March 24, 2025 IRON Sale $310,483 −4.9%+3.1%+0.8%
January 14, 2025January 10, 2025 PASG Sale $142,223 not yetnot yetnot yet
December 11, 2024December 9, 2024 PASG Sale $51,988 not yetnot yetnot yet
September 23, 2024September 19, 2024 PASG Sale $27,903 not yetnot yetnot yet
July 2, 2024June 28, 2024 TELA Sale $2,022,000 not yetnot yetnot yet
May 3, 2024May 1, 2024 NPCE Sale $409,426 −48.0%−17.6%−31.5%
April 26, 2024April 24, 2024 NPCE Sale $25,041 −49.7%−23.7%−24.7%
April 23, 2024April 19, 2024 NPCE Sale $913,057 −47.0%−24.7%−31.5%
June 29, 2023June 27, 2023 PASG Purchase $1,001,765 not yetnot yetnot yet
June 29, 2023June 27, 2023 ACET Purchase $1,828,750 not yetnot yetnot yet
April 21, 2023April 19, 2023 TELA Sale $1,792,326 −6.8%−77.2%−69.8%
April 17, 2023April 13, 2023 DMRA Sale $128,257 not yetnot yetnot yet
February 17, 2023February 15, 2023 IRON Purchase $2,500,008 +28.5%+130.2%+154.5%
November 10, 2022November 8, 2022 CMPX Purchase $1,290,420 not yetnot yetnot yet
May 13, 2022May 11, 2022 CMPX Purchase $420,482 not yetnot yetnot yet
February 19, 2021February 17, 2021 CRVS Purchase $4,499,999 not yetnot yetnot yet
September 29, 2020September 25, 2020 CALC Purchase $9,000,000 not yetnot yetnot yet
August 14, 2020August 12, 2020 INSP Sale $10,010,042 +56.3%+57.1%+43.9%
August 11, 2020August 7, 2020 INSP Sale $12,316,137 +55.8%+43.9%+63.4%
June 23, 2020June 19, 2020 CMPX Purchase $7,275,660 not yetnot yetnot yet
April 16, 2020April 14, 2020 ALEC Sale $2,009,559 −15.9%−73.7%−72.5%
April 9, 2020April 7, 2020 ALEC Sale $9,019,571 −16.7%−76.0%−70.8%
April 2, 2020March 31, 2020 ALEC Sale $6,125,000 −24.3%−77.0%−72.8%
March 25, 2020March 23, 2020 ALEC Sale $3,425,269 −4.0%−88.0%−94.4%
March 10, 2020March 6, 2020 INSP Sale $41,760,000 −4.0%+144.5%+91.1%
March 4, 2020March 2, 2020 ALEC Sale $48,729,278 −0.6%−71.2%−67.4%
December 26, 2019December 20, 2019 ALEC Sale $10,209,721 +57.7%−29.5%−35.5%
December 19, 2019December 17, 2019 ALEC Sale $17,669,932 +48.9%−35.5%−44.5%
July 1, 2019June 27, 2019 CRVS Purchase $2,444,065 −44.4%−54.1%not yet
March 11, 2019March 7, 2019 INSP Sale $20,513,512 −2.3%+35.1%+43.1%
July 2, 2018June 28, 2018 WHWK Purchase $2,993,375 not yetnot yetnot yet
May 2, 2018April 30, 2018 PVLA Sale $6,350,000 −19.2%−61.1%−65.7%
March 14, 2018March 12, 2018 CRVS Purchase $4,999,998 +27.8%−62.2%−59.7%
March 6, 2018March 2, 2018 GKOS Sale $26,787,192 +21.2%+106.5%+104.1%
February 23, 2018February 14, 2018 XTNT Purchase $6,809,897 −8.9%−48.7%not yet
February 12, 2018February 8, 2018 KALA Purchase $323,250 +16.0%−54.9%−55.6%
February 6, 2018February 2, 2018 KALA Purchase $557,383 +26.4%−52.3%−54.9%
January 30, 2018January 26, 2018 KALA Purchase $1,089,307 +10.2%−59.3%−58.7%
January 12, 2018January 10, 2018 KALA Purchase $3,192,710 +2.2%−59.3%−49.3%
February 21, 2017February 16, 2017 SYRE Purchase $563,882 −9.2%−10.7%+0.6%
August 12, 2016August 10, 2016 GKOS Sale $9,869,285 +1.7%−2.1%−6.4%
June 27, 2016June 23, 2016 CRVS Purchase $12,983 +11.4%−31.6%−33.7%
June 13, 2016June 9, 2016 CRVS Purchase $648,100 +32.9%−29.3%−41.0%
May 24, 2016May 20, 2016 CRVS Purchase $61,732 −8.3%−39.6%−39.7%
May 20, 2016May 18, 2016 CRVS Purchase $80,035 −10.9%−41.4%−20.9%
June 19, 2012June 19, 2012 AMRN Sale $7,966,761 +2.2%−72.3%−70.4%
March 28, 2011March 24, 2011 AMRN Sale $1,281,828 +104.4%+44.4%+48.7%
March 23, 2011March 21, 2011 AMRN Sale $542,850 +96.7%+48.7%+58.4%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Orbimed Advisors LLC traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.